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A B S T R A C T
Purpose
The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage
renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the
preoperative period, where there may be potential advantages including tumor downstaging. This
prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting.
Patients and Methods
Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for
nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complica-
tions, and tumor responses were monitored.
Results
Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease.
After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size
(median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using
a methodology similar to Choi criteria (median, 13%), was also observed. According to Response
Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a
partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities
from sorafenib were similar to that expected with this class of medication. All patients were able
to proceed with nephrectomy and no surgical complications related to sorafenib administration
were observed.
Conclusion
The administration of preoperative sorafenib therapy can impact the size and density of the
primary tumor and appears safe and feasible. Further studies are required to determine if
preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal
cell carcinoma.
J Clin Oncol 28:1502-1507. © 2010 by American Society of Clinical Oncology
INTRODUCTION
The advent of molecularly targeted therapeutics in
renal cell carcinoma (RCC) has ushered in a change
in the standard of care for patients with advanced
disease. Among these novel agents are the antian-
giogenic tyrosine kinase inhibitors, sorafenib and
sunitinib, the vascular endothelial growth factor
(VEGF) antibody, bevacizumab, and the mamma-
lian target of rapamycin inhibitors, temsirolimus
and everolimus. All of these drugs have gained US
Food and Drug Administration approval for use in
the metastatic setting based on pivotal phase III
studies.1-5 The establishment of efficacy in advanced
disease raises critical questions regarding the poten-
tial for application of these agents in the preopera-
tive period. As these drugs—particularly those
affecting angiogenesis—have potential for disease
volume reduction, there has been interest in their
application in the preoperative setting in hopes of
improving surgical and clinical outcomes.
Importantly, the nature of these agents’ effects
provides several hypothetical positive impacts on
immediate term clinical outcomes. Patients with lo-
calized T3 and T4, or node-positive tumors have a
very high risk for disease recurrence, and can present
complicated surgical resections. The incidence of
such presentations is uncommon, but not rare.6 The
potential to downsize tumors may afford greater
ease and safety of surgical resection, and downstag-
ing may alter the natural history of the disease.
Furthermore, first-line therapy may afford an op-
portunity for immediate systemic therapy in meta-
static patients that are marginal surgical candidates
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at the time of diagnosis, in whom the option of nephrectomy might be
reconsidered at a future time point. A somewhat different scenario is
that of the unresectable tumor. In a recent study, sunitinib was admin-
istered for an extended period of time for such patients with metastatic
disease, demonstrating that conversion to a surgically operable pri-
mary tumor is possible.7
Cytoreductive nephrectomy—surgical removal of the primary
renal tumor in the presence of metastatic disease—has been associ-
ated with improved survival in prospective randomized trials when
paired with interferon, compared with immunotherapy alone.8,9 A
critical unanswered question in contemporary practice is whether the
survival benefit associated with cytoreductive nephrectomy extends to
the era of targeted therapeutics. Immune-based treatments histori-
cally had little effect on the primary tumor, leading to a lack of preop-
erative experience in this disease.10-13 This has left the RCC field with
little precedent for any purposeful role of systemic treatment in the
presurgical setting.
Several safety concerns with the perioperative use of antiangio-
genic drugs have been raised, including the potential for delayed
wound healing, bleeding, and cardiovascular complications. A recent
report implementing bevacizumab in the preoperative setting demon-
strated the potential for tumor response, but at the expense of im-
paired wound healing.14 Currently, more objective information
regarding the use of targeted therapy in the perioperative setting is
necessary. This study is a prospective evaluation of preoperative sor-
afenib for patients at high risk for recurrence or undergoing cytore-
ductive nephrectomy, with the primary objective of determining
safety and feasibility of adjunctive systemic treatment before intended




This study was designed as a nonrandomized, open label prospective
pilot trial evaluating the use of sorafenib in the preoperative setting in patients
with clinical stage II or greater RCC. Study subjects were screened for eligibility
from patients that were identified at the University of North Carolina Multi-
disciplinary Urologic Oncology Clinic or Rex Hospital affiliate practices in
Raleigh, NC. Inclusion criteria required a minimum age of 18 years, radiolog-
ically suspicious or histologically proven clinical stage II RCC (greater than 7
cm on radiographic imaging), Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1, and planned nephrectomy of  4 weeks from enroll-
ment. This study was designed to allow patient participation during a
presurgical window of opportunity in order to avoid introducing a surgical
delay. A minimum of 4 weeks before nephrectomy date was required to ensure
adequate time for sorafenib administration. Patients who required more ur-
gent surgical accommodation due to tumor-associated symptoms (pain or
bleeding) were ineligible. This study was approved by the institutional review
board and the University of North Carolina at Chapel Hill Committee on the
Protection of the Rights of Human Subjects.
Normal renal, liver, bone marrow, and clotting function were required.
Patients were deemed ineligible if they had received any prior therapy for RCC,
had an active second malignancy, were pregnant, or had bleeding diathesis,
brain metastasis, thromboembolism, congestive heart failure, or uncontrolled
hypertension despite optimal management.
Statistical Considerations
Frequency tables, tabulating all toxicities attributed as more than likely to
be due to treatment have been reported. The proportion (reported as a per-
centage) of patients completing sorafenib therapy with a dose delay or reduc-
tion has been reported, along with exact 95% CIs. Medians, along with their
distribution-free 95% CIs, have been calculated for each of the covariates
representing the following: days of treatment before surgery, duration of
treatment, net days of treatment, days held, time of surgery, estimated blood
loss, and hospital length of stay. Difference scores have been calculated for the
paired differences between pre- and post-treatment measurements for both
longest diameter and intratumoral density. Both absolute difference scores
(pretreatment  post-treatment diameter) for comparison on the additive
scale, and natural log difference scores (log pretreatment – log post-treatment
diameter) for a proportional or percentage comparison on the multiplicative
scale have been calculated. The Wilcoxon signed-rank test was used to test if
these difference scores were significantly different from zero. All reported P
values are nominal.
Statistical analyses were performed with SAS statistical software, version
9.2 (SAS Institute Inc, Cary, NC).
Sorafenib Administration and Evaluation of Adverse Events
Sorafenib was supplied by Bayer-Onyx and administered according to
US Food and Drug Administration recommendations with a dose of 400 mg
orally on a twice daily schedule. Dose reductions were allowed for grade 3
toxicities or toxicities intolerable to the patient. Dose level 1 reduction to 200
mg twice daily was allowed. Toxicities to sorafenib therapy were graded using
the National Cancer Institute Common Toxicity Criteria for Adverse Events
version 3.0. Patients were advised to discontinue sorafenib between 24 to 48
hours before the planned surgery.
Nephrectomy Procedures
All patients underwent screening by a urologic oncologist before enroll-
ing in the trial to ensure their surgical candidacy and the appropriateness of
nephrectomy. Data regarding the time on treatment, interval between cessa-
tion of sorafenib and operative procedure, operative time for nephrectomy
procedure, toxicities to sorafenib, and surgical complications were recorded.
Evaluation of Response
All patients had chest and abdominal imaging (computed tomography
or magnetic resonance imaging) before the initiation of sorafenib therapy.
Imaging was repeated before nephrectomy to evaluate radiographic response
within the primary tumor by using RECIST (Response Evaluation Criteria in
Solid Tumors).15 Densitometric measurement of intratumoral enhancement
using a modification of the Choi criteria16 was performed to evaluate the effect
Table 1. Patient Characteristics
Characteristic No. %











Clear cell 21 70
Papillary 4 13
Mixed (clear cell/papillary) 2 7
Chromophobe 1 3
Other 2 7
Median duration of therapy, days 33
Range 8-59
Median length of time off treatment prior to
surgery, days 3
Range 2-14
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of treatment on tumor viability.17 Briefly, using axial source computed tomo-
graphy images (1.5 mm thickness) a three-dimensional image of the kidney
was reconstructed with an imaging workstation (Terra Recon, San Mateo,
CA). The largest dimensions of the primary renal tumor were outlined and a
density measurement in Hounsfield units (HU) were obtained. The percent
change in HU after treatment were recorded.
RESULTS
Patient Characteristics
The baseline characteristics of the study patients are displayed in
Table 1. Median age was 57 years (range, 22 to 84) and was represented
by 23 males (77%). The tumor histology for the group was predomi-
nantly clear cell (n  21; 70%); although both papillary and chromo-
phobe histologies were represented. Two patients with renal masses
radiographically consistent with RCC that were identified after ne-
phrectomy as having nonrenal cancers were enrolled, one urothelial
carcinoma and one liposarcoma. These two non-RCC patients were
included in the safety and toxicity analyses, but excluded from the
response analysis. Individual patient and tumor descriptions as well as
treatment response and surgical procedures are presented in Table 2.
Thirteen patients (43%) had metastatic disease (M1); while the
remaining 17 had localized disease. One patient was initially radio-
graphically staged as T4, with local muscle invasion, however, on
comparison to the post-treatment image, the primary lesion was ret-
rospectively downstaged to a T1.
Sorafenib Therapy and Adverse Events
The median number of days on sorafenib before surgery was 33
(range, 8 to 59 days). The duration of therapy varied in this study due
to its design as a window of opportunity trial. The adverse event profile
was similar to that expected for sorafenib, with the most common
adverse effects of any grade being fatigue, nausea, diarrhea, rash,
stomatitis, hypertension, and hand-foot skin reaction (Appendix Ta-
ble A1, online only). There were no grade 4 toxicities attributable to
sorafenib therapy. The proportion of patients requiring a dose reduc-
tion was 10 (33%; 95% CI, 17% to 53%) of 30. The median time off of
sorafenib before surgery was 3 days (range, 2 to 14 days).
Tumor Responses
The median primary tumor shrinkage in response to sorafenib
administration was 9.6% (range, 16% to 40%). Most patients did
achieve shrinkage of the primary tumor as shown in Figure 1A; five
patients demonstrated slight growth. The majority of patients (93%)

























1 Male 57 37 2 No LRN 137 T3aN0M0 8.6 7 19 Clear cell
2 Male 59 29 6 No LRN 132 T2N0M0 14.8 14.7 1 Myxoid liposarcoma
3 Male 53 35 2 No LRN 120 T1bN1M0 6.1 5.8 5 Mixed
4 Female 64 33 5 No LRN 190 T3aN0M0 7.8 6.9 12 Clear cell
5 Male 57 30 2 No ORN 121 T2N0M0 17 15.4 9 Clear cell
6 Male 72 24 2 No ORNCT 390 T3bN1M1 12.1 12 1 Papillary
7 Male 53 39 2 No LRNAN 108 T2N0M0 11.5 8.7 24 Clear cell
8 Male 73 35 6 No ORNCTAN 321 T4N0M1 8.8 8 9 Clear cell
9 Male 57 21 4 Yes ORNCT 113 T1bN0M0 6.5 3.9 40 Clear cell
10 Male 59 33 3 No ORNCT 484 T3cN0M1 7.8 7.8 0 Clear cell
11 Female 51 8 11 No LRNAN 101 T2N0M0 8.5 8.6 1 Chromophobe
12 Male 72 55 2 No ORN 86 T1bN0M1 4.5 3.3 27 Clear cell
13 Male 46 40 4 No LRNAN 188 T2N0M1 9 8 11 Clear cell
14 Male 69 20 2 Yes LRNAN 110 T2N0M0 7.9 7.9 0 Papillary
15 Female 50 43 2 No ORNCT 107 T3aN0M0 10.4 9.6 8 Clear cell
16 Male 53 42 4 Yes LRN 232 T2N2M1 8.8 6.5 26 Clear cell
17 Male 69 43 6 Yes LRN 82 T1aN2M1 4.2 2.7 36 Clear cell
18 Female 56 33 3 No ORN 72 T2N0M1 6.2 7.2 16 Clear cell
19 Male 58 31 3 Yes ORNCT 249 T4N0M1 10 9.7 3 Urothelial
20 Female 84 47 3 Yes ORNCT 116 T3aN2M1 12 10.8 10 Clear cell
21 Male 54 36 3 Yes LRN 158 T3N0M0 6.3 7 11 Clear cell
22 Male 48 32 6 No LRNAN 251 T2N0M0 11.5 11.6 1 Papillary
23 Male 59 18 14 No LRN 95 T2N0M0 7.6 6.2 18 Clear cell
24 Male 62 34 3 Yes LRNAN 163 T2N0M0 13.8 13.6 1 Clear cell
25 Male 47 23 4 Yes ORNCT 347 T2N0M1 6.7 5.9 12 Mixed
26 Female 22 59 3 No ORNCT 362 T2N2M0 12.4 12.1 2 Clear cell
27 Female 52 28 4 Yes ORN 116 T2N0M0 14.3 13.6 5 Clear cell
28 Male 65 10 21 No ORNCTLN 415 T4N2M0 11 11.9 8 Papillary
29 Male 49 50 2 No LRNAN 144 T1bN0M1 5.3 4.7 11 Clear cell
30 Male 51 24 2 No LRN 216 T1bN0M1 5.8 4.6 21 Clear cell
Abbreviations: LD, longest dimension; LRN, laparoscopic radical nephrectomy; ORN, open radical nephrectomy; CT, caval thrombectomy; AN, adrenalectomy.
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met RECIST for stable disease. Two patients met criteria for partial
response and no patients had either confirmed progressive disease
or complete response. Both the absolute and logarithmic differ-
ences between the pretreatment and post-treatment tumor diam-
eters were found to be significantly decreased (P  .0001 and
P  .0001, respectively).
Radiographic intratumoral changes were also examined. The
loss of contrast enhancement centrally within the tumor is consis-
tent with intratumoral necrosis, and represents an alternative radio-
graphic assessment of response to targeted therapy.17 An assessment of
intratumoral enhancement was performed on the subset of patients
who underwent contrast-enhanced computed tomography imaging
before and after sorafenib treatment. Within these 17 evaluable pa-
tients, decrease in intratumoral density was observed in 15 patients
(Fig 1B), with a median decrease in enhancement of 13%. As seen with
dimensional response, the change in intratumoral enhancement
was significant for both absolute or percentage measurements (P 
.0007 and P  .003, respectively).
Four patients were downstaged from T2 to T1 lesions. Ten pa-
tients had T3 or T4 lesions, including cases of renal vein or inferior
vena cava involvement present at all levels, including disease extend-
ing into the right atrium. None demonstrated disease progression
within the vasculature during sorafenib treatment. Two patients with
radiographic evidence of renal vein thrombus were pathologically
negative for renal vein extension on nephrectomy. Response to ther-
apy did not alter surgical approach (ie, laparoscopic v open) from the
plan at the time of study enrollment in any patient in this series.
Nephrectomy Procedures and Surgical Complications
Surgical outcomes after preoperative therapy are presented in
Table 3. Sixteen patients (53%) underwent laparoscopic radical ne-
phrectomy; fourteen (47%) had open nephrectomy. Ten patients
underwent caval thrombectomy and five had adrenalectomy in addi-
tion to their primary surgical procedure. For laparoscopic and open
procedures the median operative time was 135 minutes (95% CI, 108
to 190 minutes) and 185 minutes (95% CI, 113 to 390 minutes),
respectively; compared to the average institutional duration for lapa-
roscopic and open nephrectomies (years 2006 to 2008) of 182 and 211
minutes, respectively. No complications of delayed wound healing,
surgical dehiscence, or excessive bleeding were observed. One patient
had a superficial wound breakdown postoperatively (postoperative
day 8), which responded to conservative management. One patient
suffered a postoperative myocardial infarction on postoperative day 1
in the setting of an extensive surgical resection with caval thrombec-
tomy and adrenalectomy. The median estimated blood loss for pa-
tients receiving laparoscopic and open procedures was 150 mL (95%
CI, 100 to 200 mL) and 950 mL (95% CI, 200 to 3,000 mL), respec-
tively. The average length of hospital stay for patients having laparo-
scopic and open nephrectomies was 3.7 days (95% CI, 3 to 4 days) and























































Median pretreatment LD 8.7 cm (range, 4.2 to 17)
Median post-treatment LD 7.9 cm (range, 2.7 to 15.4)
P = .0001, Wilcoxon signed-rank test
Median pretreatment density 55 HU (range, 25 to 102)
Median post-treatment density 47 HU (range, 29 to 102)
P = .003, Wilcoxon signed-rank test
Fig 1. Waterfall plot distributions of primary tumor responses. (A) Waterfall plot
of size response. Response Evaluation Criteria in Solid Tumors partial response
criteria designated by lower dashed line at 30% and progressive disease criteria
designated by upper dashed line at 20%. (B) Waterfall plot of intratumoral
enhancement response. Change in contrast enhancement of the primary tumors,
17 patients evaluable (Hounsfield units [HU]). LD, longest dimension.









Median 95% CI Median 95% CI Median 95% CI Median 95% CI
No. 16 — — 14 — —
% 53 47
Operative time, minutes 135 108 to 190 182 185 113 to 390 211
Estimated blood loss, mL 150 100 to 200 — — 950 200 to 3,000 — —
Length of hospital stay, days 4 3 to 4 — — 6 5 to 13 — —
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Clinical Outcomes
Currently only two of the 15 patients with localized disease have
relapsed after surgery (both stage III) after a median follow-up of 217
days. Those patients with metastatic disease at the time of enrollment
were routinely restarted on systemic therapy postoperatively, but only
after 4 to 6 weeks and when wound closure was secure. These patients
were managed in a variety of ways including therapy with high-dose
interleukin-2 (n  1), temsirolimus (n  1), further tyrosine kinase
inhibitor (sorafenib n  3, sunitinib n  5), and even a period of
monitoring off therapy (n  2). Decisions regarding subsequent ther-
apy postnephrectomy were determined on a patient-by-patient basis.
DISCUSSION
Great interest has emerged in establishing the value of combining new
molecularly targeted therapeutics with the standard practices of cy-
toreductive or curative nephrectomy. Many questions regarding
longer-term clinical outcomes with these novel approaches remain
unanswered at the moment; however, this prospective study of sor-
afenib in the preoperative setting provides important information to
address concerns for safety and feasibility. In this study, sorafenib was
well tolerated with no unexpected adverse events.
The study was designed to evaluate primary tumor response to
therapy synchronously with surgery to avoid any potential compli-
cations due to rebound growth with a more prolonged wash-out
period before surgery. No adverse surgical complications were
observed even though patients discontinued therapy a brief me-
dian of 3 days before the operation. Sorafenib is advantageous in
this regard due to its shorter half-life (25 to 48 hours) compared to
sunitinib (40 to 60 hours; active metabolite, 80 to 110 hours) and
bevacizumab (20 days; range, 11 to 50 days). There are benefits
and drawbacks to any of the VEGF-targeted agents in this setting,
and the optimal therapeutic agent in this setting remains to be
clarified as we gain further experience with treatment in the pre-
operative setting.7,14,18
The optimal duration of preoperative therapy is also uncertain.
In the Treatment Approaches in Renal Cancer Global Evaluation Trial
study, patients with complete or partial response achieved best re-
sponse in a median of 80 days.1 However, delaying nephrectomy for
an extended period of time may be unacceptable. This study used an
interval of 4 to 8 weeks of therapy as a time frame which approximates
two cycles of treatment, when repeat imaging is typically obtained.
Biopsy was not mandated in this trial leading to two non-RCC
lesions being treated, a liposarcoma and an urothelial carcinoma.
These occurrences demonstrate the inability of radiographic imaging
to conclusively diagnose renal cell carcinoma and supports the neces-
sity of pretreatment biopsy prior embarking on preoperative sys-
temic therapy.
The effect of sorafenib on the primary tumor was previously
undocumented, and in this study, we observed a size decrease in the
primary tumor in the majority of patients; two had partial responses
using standard RECIST. Although not a validated end point for mea-
suring tumor responses to VEGF-targeted therapy, the effect of sor-
afenib therapy on intratumoral enhancement of the primary tumor
was measured, demonstrating a similarly significant effect on the
primary tumor. Prior studies have confirmed that this radiographic
change represents the accumulation of tumor necrosis,17 thus poten-
tially adding to the evidence in support of a potent effect of targeted
therapy on the cells of the primary tumor.
The results of our investigation further substantiate the findings
of other recently published retrospective reports which suggest the
utility of this multimodality approach to impact primary tumors, and
in some cases render unresectable tumors resectable.18-22 Although no
objective criteria exist to reproducibly define surgical resectability, the
situation in which a tumor is not resectable due to size or local invasion
occurs, although infrequently. This scenario represents an ideal setting
for preoperative therapy, to the extent that a given agent may yield
tumor volume reduction. Two recent series of patients treated preop-
eratively with intent to improve surgical candidacy have been pub-
lished. In the first series, 19 patients with inoperable tumors were
treated with sunitinib until they were deemed operable.7 Four patients
were able to proceed with nephrectomy due to tumor downstaging
after 6 months median follow-up, and no surgical complications were
reported. In a similar retrospective analysis, three of 10 patients with
inoperable tumors were able to be converted to operable candidates
with sunitinib preoperative therapy.23
The tumor downstaging effect of targeted therapeutics such as
sorafenib thus offers several potential advantages. In extreme cases it
may afford the chance to render a difficult resection possible, and
downstaging may impact the natural history of the disease with de-
creased risk of recurrence. Demonstration of clinical response in the
cytoreductive setting may serve as a litmus test of response to targeted
therapy. Certainly larger studies with longer follow-up are required to
demonstrate such benefits, but these factors provide a lens through
which we might begin to conceptualize the rationale for neoadjuvant
therapy in RCC. In addition to potential direct clinical benefit to the
patient, preoperative use of systemic therapy also affords the oppor-
tunity for sample collection to explore for predictive or pharmacody-
namic correlative biologic markers.
This pilot study is limited by its small sample size, and the mix-
ture of patients with localized and metastatic disease and varied his-
tologies precludes a robust analysis of clinical end points. In addition,
duration of therapy in this study varied as it was conceived with a
window of opportunity design; continuing therapy to maximum tu-
mor response may also be a reasonable approach. The selection of
preoperative therapy should be considered with care. Among the
tyrosine kinase inhibitors, sunitinib is more widely used in the first-
line setting due to its reported superior response rate and progression-
free survival and may warrant consideration in selected cases;
however, the surgical findings with neoadjuvant sorafenib cannot be
assumed to translate across therapies. Data is emerging from studies
with both sunitinib and bevacizumab, as well as sorafenib, to enable
clinicians to evaluate the relative risks and benefits of these biologic
agents in the preoperative setting.
Based on our findings, sorafenib administration in the preop-
erative setting is safe and feasible and use of this class of agents
should be considered for evaluation in larger prospective neoadju-
vant trials designed to evaluate recurrence and survival end points
for high-risk localized RCC. Future trials should be designed to
address survival end points as combined-modality therapy in both
locally advanced and metastatic renal cell carcinoma patients is
further explored.
Cowey et al
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